LeMaitre Vascular Q2 FY26 EPS rises 23% to $0.74; net sales increase 10% to $70.4 million
LMAT•Product performance
Artegraft sales increased 34%; catheters fell 11% due to recall-driven overstocking in Q2 2025.
Guidance for Q3 and full year
Guidance calls for Q3 net sales of $66.3 million-$68.3 million, EPS of $0.66-$0.71; full-year net sales of $274.3 million-$278.3 million, EPS of $2.84-$2.94.
Q2 results and operating performance
LeMaitre Vascular posted Q2 net sales of $70.4 million, up 10% year over year; diluted EPS climbed 23% to $0.74.
Operating income rose 26% to $20.4 million; gross margin widened 2.1 percentage points to 72.1%.
Cash increased $9 million sequentially to $376.2 million; a $0.25-per-share quarterly dividend is payable Sept. 3 to holders of record Aug. 20.
